4/5Liminatus Pharma, Inc. (LIMN): Going-concern doubt

Market data

Price before filing: $271.5 (2025-05-30 close, split/dividend-adjusted)
Market cap at flag: $125.6M (2025-06-02) · Latest: $1.4M (2026-10-16)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after: none reported.

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-03-04 to 2025-07-02. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"As such, this raises substantial doubt about the Company's ability to continue as a going concern."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Source: management disclosure in Form 10-Q (period 2025-03-31)

Why this score: quarterly (unaudited) disclosure; also within 90 days: Auditor change, Late quarterly report (NT 10-Q)